Progress in the molecular biology of Ewing tumors

Sarcoma

Volumn 2, Issue 1, 1998, Pages 3-17

  Kovar, Heinrich ^a  

^a CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

Author keywords

ETS; EWS; IGF1; Prognosis; Tumor suppressor

Indexed keywords

DNA; HYBRID PROTEIN; RECOMBINASE; TRANSCRIPTION FACTOR;

CHROMOSOME TRANSLOCATION 11; DNA BINDING; EWING SARCOMA; GENE FUSION; GENE REARRANGEMENT; HUMAN; MOLECULAR BIOLOGY; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN CONFORMATION; REVIEW; TRANSCRIPTION REGULATION;

EID: 0031866168     PISSN: 1357714X     EISSN: None     Source Type: Journal    
DOI: 10.1080/13577149878109     Document Type: Review

References (128)

1. Kovar H, Zoubek A, Gadner H. A long way from the definition of the molecular basis to benefit in the clinical management of Ewing tumours. Onkologie 1996; 19:234-40.
2. Turc Carel C, Aurias A, Mugneret F, et al. Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24;q12). Cancer Genet Cytogenet 1988; 32:229-38.
3. Aurias A [Cytogenetic data on sarcomas of the bone and soft tissue] Donnees cytogenetiques dans les sarcomes des os et des tissus mous. Bull Cancer Paris 1988; 75:423-9.
4. Turc Carel CS. [Contribution of cytogenetics to the diagnosis of Ewing's sarcoma and small round cell tumors] Apport de la cytogenetique au diagnostic du sarcome d'Ewing's et des tumeurs a petites cellules rondes. Bull Cancer Paris 1991; 78:77-84.
5. Hamilton G, Fellinger EJ, Schratter I, et al. Characterization of a human endocrine tissue and tumor-associated Ewing's sarcoma antigen. CancerRes 1988; 48:6127-31.
6. Banting GS, Pym B, Darling SM, et al. The MIC2 gene product: epitope mapping and structural prediction analysis define an integral membrane protein. Mol Immunol 1989; 26:181-8.
7. Kovar H, Dworzak M, Strehl S, et al. Overexpression of the pseudoautosomal gene MIC2 in Ewing's sarcoma and peripheral primitive neuroectodermal tumor. Oncogene 1990; 5:1067-70.
8. Ambros IM, Ambros PF, Strehl S, et al. MIC2 is a specific marker for Ewing's sarcoma and peripheral primitive neuroectodermal tumors Evidence for a common histogenesis of Ewing's sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration. Cancer 1991; 67:1886-93.
9. Fellinger EJ, Garin Chesa P, Triche TJ, et al. Immunohistochemical analysis of Ewing's sarcoma cell surface antigen p30/32MIC2. Am J Pathol 1991; 139:317-25.
10. Levy R, Dilley J, Fox RI, et al. A human thymus-leukemia antigen defined by hybridoma monoclonal antibodies. Proc Natl Acad Sci USA 1979; 76:6552-6.
11. Dworzak MN, Fritsch G, Buchinger P, et al. Flow cytometric assessment of human MIC2 expression in bone marrow, thymus, and peripheral blood. Blood 1994; 83:415-25.
12. Riopel M, Dickman PS, Link MP, et al. MIC 2 analysis in pediatric lymphomas and leukemias. Hum Pathol 1994; 25 :396-9.
13. Zucman J, Delattre O, Desmaze C, et al. Cloning and characterization of the Ewing's sarcoma and peripheral neuroepithelioma t(11;22) translocation break-points. Genes Chromosomes Cancer 1992; 5:271-7.
14. Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992; 359:162-5.
15. Adams V, Hany MA, Schmid M, et al. Detection of t(11;22)(q24;q12) translocation break-point in paraffin-embedded tissue of the Ewing's sarcoma family by nested reverse transcription-polymerase chain reaction. Diagn Mol Pathol 1996; 5:107-13.
16. Delattre O, Zucman J, Melot T, et al. The Ewing's family of tumors - a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med 1994; 331:294-9.
17. Scotlandi K, Serra M, Manara MC, et al. Immunostaining of the p30/32MIC2 antigen and molecular detection of EWS rearrangements for the diagnosis of Ewing's sarcoma and peripheral neuroectodermal tumor. Hum Pathol 1996; 27:408-16.
18. Zoubek A, Dockhorn Dworniczak B, Delattre O, et al. Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing's tumor patients? J Clin Oncol 1996; 14:1245-51.
19. Jeon IS, Davis JN, Braun BS, et al. A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. Oncogene 1995; 10:1229-34.
20. Kaneko Y, Yoshida K, Handa M, et al. Fusion of an ETS-family gene, E1AF, to EWS by t(17;22)(q12;q12) chromosome translocation in an undifferentiated sarcoma of infancy. Genes Chromosomes Cancer 1996; 15:115-21.
21. Peter M, Couturier J, Pacquement H, et al. A new member of the ETS family fused to EWS in Ewing tumors. Oncogene 1997; 14:1159-64.
22. Sorensen PH, Lessnick SL, Lopez Terrada D, et al. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet 1994; 6:146-51.
23. Urano F, Umezawa A, Hong W, et al. A novel chimera gene between EWS and E1A-F, encoding the adenovirus E1A enhancer-binding protein, in extraosseous Ewing's sarcoma. Biochem Biophys Res Commun 1996; 219:608-12.
24. Zucman J, Melot T, Desmaze C, et al. Combinatorial generation of variable fusion proteins in the Ewing's family of tumours. EMBOJ 1993; 12:4481-7.
25. Ladanyi M, Lewis R, Garin-Chesa P, et al. EWS rearrangement in Ewing's sarcoma and peripheral neuroectodermal tumor. Molecular detection and correlation with cytogenetic analysis and MIC2 expression. Diagn Mol Pathol 1993; 2:141-6.
26. Sorensen PH, Shimada H, Liu XF, et al. Biphenotypic sarcomas with myogenic and neural differentiation express the Ewing's sarcoma EWS/FLI1 fusion gene. Cancer Res 1995; 55:1385-92.
27. Thorner P, Squire J, Chilton MacNeil S, et al. Is the EWS/FLI-1 fusion transcript specific for Ewing's sarcoma and peripheral primitive neuroectodermal tumor? A report of four cases showing this transcript in a wider range of tumor types. Am J Pathol 1996; 148:1125-38.
28. Sorensen PH, Wu JK, Berean KW, et al. Olfactory neuroblastoma is a peripheral primitive neuroectodermal tumor related to Ewing's sarcoma. Proc Natl Acad Sci USA 1996; 93:1038-43.
29. Devaney K, Wenig BM, Abbondanzo SL. Olifactory neuroblastoma and other round cell lesions of the sinonasal region. Mod Pathol 1996; 9:658-63.
30. Burchill SA, Wheeldon J, Cullinane C, et al. EWS-FLI1 fusion transcripts identified in patients with typical neuroblastoma. Eur J Cancer 1997; 33:239-43.
31. Desmaze C, Zucman J, Delattre O, et al. Interphase molecular cytogenetics of Ewing's sarcoma and peripheral neuroepithelioma t(11;22) with flanking and overlapping cosmid probes. Cancer Genet Cytogenet 1994; 74:13-8.
32. Desmaze C, Zucman J, Delattre O, et al. Unicolor and bicolor in situ hybridization in the diagnosis of peripheral neuroepithelioma and related tumors. Genes Chromosomes Cancer 1992; 5:30-4.
33. Crozat A, Aman P, Mandahl N, et al. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature 1993; 363:640-4.
34. Rabbitts TH, Forster A, Larson R, et al. Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma. Nat Genet 1993; 4:175-80.
35. Zinszner H, Albalat R, Ron D. A novel effector domain from the RNA-binding protein TLS or EWS is required for oncogenic transformation by CHOP. Genes Dev 1994; 8:2513-26.
36. Bertolotti A, Lutz Y, Heard DJ, et al. hTAF(II)68, a novel RNA/ssDNA-binding protein with homology to the pro-oncoproteins TLS/FUS and EWS is associated with both TFIID and RNA polymerase II. EMBO J 1996; 15:5022-31.
37. Hackl W, Luhrmann R. Molecular cloning and subcellular localisation of the snRNP associated protein 69KD, a structural homologue of the proto-oncoproteins TLS and EWS with RNA and DNA-binding properties. J Mol Biol 1996; 264:843-51.
38. Alliegro MC, Alliegro MA. A nuclear protein regulated during the transition from active to quiescent phenotype in cultured endothelial cells. Dev Biol 1996; 174:288-97.
39. Immanuel D, Zinszner H, Ron D. Association of SARFH (sarcoma-associated RNA-binding fly homolog) with regions of chromatin transcribed by RNA polymerase II. Mol Cell Biol 1995; 15:4562-71.
40. Stolow DT, Haynes SR. Cabeza, a Drosophila gene encoding a novel RNA binding protein, shares homology with EWS and TLS, two genes involved in human sarcoma formation. Nucleic Acids Res 1995; 23:835-43.
41. Burd CG, Dreyfuss G. Conserved structures and diversity of functions of RNA-binding proteins. Science 1994; 265:615-21.
42. Courey AJ, Tjian R. Analysis of Sp1 in vivo reveals multiple transcriptional domains, including a novel glutamine-rich activation motif. Cell 1988; 55:887-98.
43. Plougastel B, Zucman J, Peter M, et al. Genomic structure of the EWS gene and its relationship to EWSR1, a site of tumor-associated chromosome translocation. Genomics 1993; 18:609-15.
44. Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992; 359:162-5.
45. Calvio C, Neubauer G, Mann M, et al. Identification of hnRNP P2 as TLS/FUS using electrospray mass spectrometry. RNA 1995; 1:724-33
46. Alliegro MC, Alliegro MA Identification of a new coiled body component. Exp Cell Res 1996; 227:386-90.
47. Zinszner H, Immanuel D, Yin Y, et al. A topogenic role for the oncogenic N-terminus of TLS: nucleolar localization when transcription is inhibited. Oncogene 1997; 14:451-61.
48. Panagopoulos I, Hxglund M, Mertens F, et al. Fusion of the EWS and CHOP genes in myxoid liposarcoma. Oncogene 1996; 12:489-94.
49. Ichikawa H, Shimizu K, Hayashi Y, et al. An RNA-binding protein gene, TLS/FUS, is fused to ERG in human myeloid leukemia with t(16;21) chromosomal translocation. Cancer Res 1994; 54:2865-8.
50. Panagopoulos I, Aman P, Fioretos T, et al. Fusion of the FUS gene with ERG in acute myeloid leukemia with t(16;21)(p11;q22). Genes Chromosomes Cancer 1994; 11:256-62.
51. Kong XT, Ida K, Ichikawa H, et al. Consistent detection of TLS/FUS-ERG chimeric transcripts in acute myeloid leukemia with t(16;21)(p11;q22) and identification of a novel transcript. Blood 1997; 90:1192-9.
52. Clark J, Benjamin H, Gill S, et al. Fusion of the EWS gene to CHN, a member of the steroid/thyroid receptor gene superfamily, in a human myxoid chondrosarcoma. Oncogene 1996; 12:229-35.
53. Ladanyi M, Gerald W. Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor. Cancer Res 1994; 54:2837-40.
54. Zucman J, Delattre O, Desmaze C, et al. EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts. Nat Genet 1993; 4:341-5.
55. Labelle Y, Zucman J, Stenman G, et al. Oncogenic conversion of a novel orphan nuclear receptor by chromosome translocation. Hum Mol Genet 1995; 4:2219-26.
56. Zucman Rossi J, Batzer MA, Stoneking M, et al. Interethnic polymorphism of EWS intron 6: genome plasticity mediated by Alu retroposition and recombination. Hum Genet 1997; 99:357-63.
57. Rudiger NS, Gregersen N, Kielland Brandt MC. One short well conserved region of Alu-sequences is involved in human gene rearrangements and has homology with prokaryotic chi. Nucleic Acids Res 1995; 23:256-60.
58. Parkin DM, Stiller CA, Nectoux J. International variations in the incidence of childhood bone tumours. Int J Cancer 1993; 53:371-6.
59. Stiller CA, Parkin DM. Geographic and ethnic variations in the incidence of childhood cancer. Br Med Bull 1996; 52:682-703.
60. Bhagirath T, Abe S, Nojima T, et al. Molecular analysis of a t(11;22) translocation junction in a case of Ewing's sarcoma. Genes Chromosomes Cancer 1995; 13:126-32.
61. Liu J, Nau MM, Zucman Rossi J, et al. LINE-I element insertion at the t(11;22) translocation breakpoint of a desmoplastic small round cell tumor. Genes Chromosomes Cancer 1997; 18:232-9.
62. Peter M, Mugneret F, Aurias A, et al. An EWS/ERG fusion with a truncated N-terminal domain of EWS in a Ewing's tumor. Int J Cancer 1996; 67:339-42.
63. Kaneko Y, Kobayashi H, Handa M, et al. EWS-ERG fusion transcript produced by chromosomal insertion in a Ewing's sarcoma. . Genes Chromosomes Cancer 1997; 18:228-31.
64. Selleri L, Giovannini M, Romo A, et al Cloning of the entire FLI1 gene, disrupted by the Ewing's sarcoma translocation breakpoint on 11q24, in a yeast artificial chromosome. Cytogenet Cell Genet 1994; 67:129-36.
65. Zucman Rossi J, Legoix P, Thomas G. Identification of new members of the Gas2 and Ras families in the 22q12 chromosome region Genomics 1996; 38:247-54.
66. Meyer D, Wolff CM, Stiegler P, et al. X1-fli, the Xenopus homologue of the fli-1 gene, is expressed during embryogenesis in a restricted pattern evocative of neural crest cell distribution. Mech Dev 1993; 44:109-21
67. Bailly RA, Bosselut R, Zucman J, et al. DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing's sarcoma. Mol Cell Biol 1994; 14:3230-41.
68. Ohno T, Rao VN, Reddy ES. EWS/Fli-1 chimeric protein is a transcriptional activator. Cancer Res 1993; 53:5859-63.
69. Prasad DD, Ouchida M, Lee L, et al. TLS/FU fusion domain of TLS/FUS-erg chimeric protein resulting from the t(16;21) chromosomal translocation in human myeloid leukemia functions as a transcriptional activation domain. Oncogene 1994; 9:3717-29.
70. Donaldson LW, Petersen JM, Graves BJ, et al. Solution structure of the ETS domain from murine Ets-1:a winged helix-turn-helix DNA binding motif. EMBO J 1996; 15:125-34.
71. Liang H, Olejniczak ET, Mao X, et al The secondary structure of the ets domain of human Fli-1 resembles that of the helix-turn-helix DNA-binding motif of the Escherichia coli catabolite gene activator protein. Proc Natl Acad Sci USA 1994; 91:11655-9
72. Liang H, Mao X, Olejniczak ET, et al. Solution structure of the ets domain of Fli-1 when bound to DNA. Nat Struct Biol 1994; 1:871-5.
73. Jonsen MD, Petersen JM, Xu QP, et al. Characterization of the cooperative function of inhibitory sequences in Ets-1. Mol Cell Biol 1996; 16:2065-73.
74. Petersen JM, Skalicky JJ, Donaldson LW, et al. Modulation of transcription factor Ets-1 DNA binding: DNA-induced unfolding of an alpha helix. Science 1995; 269:1866-9.
75. Wasylyk B, Hahn SL, Giovane A. The Ets family of transcription factors [published erratum appears In Eur J Biochem 1993 Aug 1;215(3):907]. Eur J Biochem 1993; 211:7-18.
76. Werner MH, Clore M, Fisher CL, et al. The solution structure of the human ETS1-DNA complex reveals a novel mode of binding and true side chain intercalation. Cell 1995; 83:761-71.
77. Macleod K, Leprince D, Stehelin D. The ets gene family. Trends Biochem Sci 1992; 17:251-6.
78. Fitzsimmons D, Hodsdon W, Wheat W, et al. Pax-5 (BSAP) recruits Ets proto-oncogene family proteins to form functional ternary complexes on a B-cell-specific promoter. Genes Dev 1996; 10:2198-211.
79. Jousset C, Carron C, Boureux A, et al. A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL-PDGFR beta oncoprotein. EMBO J 1997; 16:69-82.
80. Braun BS, Frieden R, Lessnick SL, et al. Identification of target genes for the Ewing's sarcoma EWS/FLI fusion protein by representational difference analysis. Mol Cell Biol 1995; 15:4623-30.
81. Thompson AD, Braun BS, Arvand A, et al. EAT-2 is a novel SH2 domain containing protein that is up regulated by Ewing's sarcoma EWS/FLI1 fusion gene. Oncogene 1996; 13:2649-58.
82. Kaya M, Yoshida K, Higashino F, et al. A single ets-related transcription factor, E1AF, confers invasive phenotype on human cancer cells. Oncogene 1996; 12:221-7.
83. Hida K, Shindoh M, Yasuda M, et al. Antisense E1AF transfection restrains oral cancer invasion by reducing matrix metalloproteinase activities. Am J Pathol 1997; 150:2125-32.
84. Wasylyk C, Gutman A, Nicholson R, et al. The c-Ets oncoprotein activates the stromelysin promoter through the same elements as several non-nuclear oncoproteins. EMBO J 1991; 10:1127-34.
85. Buttice G, Duterque Coquillaud M, Basuyaux JP, et al. Erg, an Ets-family member, differentially regulates human collagenase1 (MMP1) and stromelysin 1 (MMP3) gene expression by physically interacting with the Fos/Jun complex. Oncogene 1996; 13:2297-306.
86. Kovar H, Aryee DN, Jug G, et al. EWS/FLI-1 antagonists induce growth inhibition of Ewing's tumor cells in vitro. Cell Growth Differ 1996; 7:429-37.
87. Pingoud V, Zinck R, Hipskind RA, et al. Heterogeneity of ternary complex factors in HeLa cell nuclear extracts. J Biol Chem 1994; 269:23310-7.
88. Magnaghi Jaulin L, Masutani H, Robin P, et al. SRE elements are binding sites for the fusion protein EWS-FLI-1. Nucleic Acids Res 1996; 24:1052-8.
89. Watson DK, Robinson L, Hodge DR, et al. FLI1 and EWS-FLI1 function as ternary complex factors and ELK1 and SAP1a function as ternary and quaternary complex factors on the Egr1 promoter serum response elements Oncogene 1997; 14:213-21.
90. Cavazzana AO, Miser JS, Jefferson J, et al. Experimental evidence for a neural origin of Ewing's sarcoma of bone. Am J Pathol 1987; 127:507-18.
91. Ben David Y, Giddens EB, Letwin K, et al. Erythroleukemia induction by Friend murine leukemia virus: insertional activation of a new member of the ets gene family, Fli-1, closely linked to c-ets-1. Genes Dev 1991; 5:908-18.
92. Howard JC, Yousefi S, Cheong G, et al. Temporal order and functional analysis of mutations within the Fli-1 and p53 genes during the erythroleukemias induced by F-MuLV. Oncogene 1993; 8:2721-9
93. Hart AH, Corrick CM, Tymms MJ, et al. Human ERG is a proto-oncogene with mitogenic and transforming activity Oncogene 1995; 10:1423-30
94. Lessnick SL, Braun BS, Denny CT, et al. Multiple domains mediate transformation by the Ewing's sarcoma EWS/FLI-1 fusion gene. Oncogene 1995; 10:423-31.
95. May WA, Gishizky ML, Lessnick SL, et al. Ewing's sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc Natl Acad Sci USA 1993; 90:5752-6
96. Toretsky JA, Connell Y, Neckers L, et al Inhibition of EWS-FLI-1 fusion protein with antisense oligodeoxynucleotides. J Neurooncol 1997; 31:9-16.
97. Tanaka K, Iwakuma T, Harimaya K, et al. EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. J Clin Invest 1997; 99:239-47.
98. Ouchida M, Ohno T, Fujimura Y, et al. Loss of tumorigenicity of Ewing's sarcoma cells expressing antisense RNA to EWS-fusion transcripts. Oncogene 1995; 11:1049-54
99. Toretsky JA, Kalebic T, Blakesley V, et al. The insulin-like growth factor-1 receptor is required for EWS/FLI1 transformation of fibroblasts. J Biol Chem 1997; 272:30822-7.
100. Hofbauer S, Hamilton G, Theyer G, et al. Insulin-like growth factor-I-dependent growth and in vitro chemosensitivity of Ewing's sarcoma and peripheral primitive neuroectodermal tumour cell lines. Eur J Cancer 1993; 29A:241-5.
101. van Valen F, Winkelmann W, Jurgens H. Type I and type II insulin-like growth factor receptors and their function in human Ewing's sarcoma cells. J Cancer Res Clin Oncol 1992; 118:269-75.
102. Yee D, Favoni RE, Lebovic GS, et al. Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor. J Clin Invest 1990; 86:1806-14.
103. Scotlandi K, Benini S, Sarti M, et al. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res 1996; 56:4570-4.
104. Baserga R, Hongo A, Rubini M, et al. The IGF-I receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta 1997; 1332:F105-26.
105. Yi H, Fujimura Y, Ouchida M, et al. Inhibition of apoptosis by normal and aberrant Fli-1 and erg proteins involved in human solid tumors and leukemias. Oncogene 1997; 14:1259-68.
106. Mugneret F, Lizard S, Aurias A, et al. Chromosomes in Ewing's sarcoma. II. Nonrandom additional changes, trisomy 8 and der(16)t(1;16). Cancer Genet Cytogenet 1988; 32:239-45.
107. Armengol G, Tarkkanen M, Virolainen M, et al. Recurrent gains of 1q, 8 and 12 in the Ewing's family of tumours by comparative genomic hybridization. Br. J Cancer 1997; 75:1403-9.
108. Jost CA, Marin MC, Kaelin WG, Jr. p73 is a human p53-related protein that can induce apoptosis. Nature 1997; 389:191-4.
109. Kaghad M, Bonnet H, Yang A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997; 90:809-19.
110. Kovar H, Auinger A, Jug G, et al. Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing's tumours. Oncogene 1993; 8:2683-90.
111. Ladanyi M, Lewis R, Jhanwar SC, et al. MDM2 and CDK4 gene amplification in Ewing's sarcoma. J Pathol 1995; 175:211-7.
112. Aryee DN, Strobel T, Kos K, et al. High nm23-H1/NDPK-A expression in Ewing's tumors: paradoxical immunohistochemical reactivity and lack of prognostic significance. Int J Cancer 1995; 64:104-11.
113. Kovar H, Jug G, Aryee DNT, et al. Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing's family of tumors. Oncogene 1997; 15:2225-32.
114. MacLachlan TK, Sang N, Giordano A. Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer. Crit Rev Eukaryot Gene Expr 1995; 5:127-56.
115. Hamelin R, Zucman J, Melot T, et al p53 mutations in human tumors with chimeric EWS/FLI-1 genes. Int J Cancer 1994; 57:336-40.
116. Kovar H, Jug G, Gadner H. Variable proportion of tumor cells refractory to p53 mediated apoptosis: a mechanism of therapy resistance in Ewing's tumors? Med Ped Oncol 1997; 29:327
117. Prasad SC, Thraves PJ, Bhatia KG, et al. Enhanced poly(adenosine diphosphate ribose) polymerase activity and gene expression in Ewing's sarcoma cells. Cancer Res 1990; 50:38-43.
118. Peter M, Magdelenat H, Michon J, et al. Sensitive detection of occult Ewing's cells by the reverse transcriptase-polymerase chain reaction. Br J Cancer 1995; 72:96-100.
119. Pfleiderer C, Zoubek A, Gruber B, et al. Deflection of tumour cells in peripheral blood and bone marrow from Ewing's tumour patients by RT-PCR. Int J Cancer 1995; 64:135-9.
120. Zoubek A, Kovar H, Kronberger M, et al. Mobilization of tumour cells during biopsy in an infant with Ewing's sarcoma. Eur J Pediatr 1996; 155:373-6.
121. Zoubek A, Ladenstein R, Windhager R, et al. Predictive potential of testing for bone marrow involvement in Ewing's tumor patients by RT-PCR: a preliminary evaluation. Int J Cancer 1998; 79:56-60.
122. Tanaka K, Iwakuma T, Harimaya K, et al. EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. J Clin Invest 1997; 99:239-47.
123. Mao X, Miesfeldt S, Yang H, et al. The FLI-1 and chimeric EWS-FLI-1 oncoproteins display similar DNA binding specificities. J Biol Chem 1994; 269:18216-22.
124. Zoubek A, Pfleiderer C, Ambros PF, et al. Minimal metastatic and minimal residual disease in patients with Ewing's tumors. Klin Pädiatr 1995; 207:242-7.
125. Petermann R, Mossier B, Aryee DNT, et al. Oncogenic EWS-FLI1 interacts with hsRPB7, a subunit of human RNA polymerase II. Oncogene 1998; in press.
126. Bertolotti A, Melot T, Acker J, et al. EWS, but not EWS-Fli1, is associated with both TFIID and RNA polymerase II: Interactions between two members of the TET family, EWS and hTAFII68, and subunits of TFIID and RNA polymerase II subcomplexes. Mol Cell Biol 1998; 18:1489-97.
127. Aryee DNT, Petermann R, Kos K, et al. Cloning of a novel human ELF-1-related ETS transcription factor, ELFR, its characterization and chromosomal assignment relative to ELF-1. Gene 1998; 210:71-8.
128. De Alava E, Kawai A, Healey JA, et al. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol 1998; 16:1248-55.